预约演示
更新于：2025-07-19
Deoxycholic Acid
脱氧胆酸
更新于：2025-07-19
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (2015-04-29), |
最高研发阶段(中国)无进展 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C24H40O4 |
InChIKeyKXGVEGMKQFWNSR-LLQZFEROSA-N |
CAS号83-44-3 |
关联
45
项与 脱氧胆酸 相关的临床试验NCT06783621
US HARMONY in DIVERSITY: A Prospective, Open-label Study to Evaluate Subject Satisfaction With the Overall Face and Neck Appearance After Combined Treatment
IRCT20240416061507N1
Evaluating the efficacy and safety of Deoxycholic acid injection (Embella®) in reduction of flank fat
IRCT20240416061507N2
Evaluating the efficacy and safety of Deoxycholic acid injection (Embella®) in management of superficial lipomas
100 项与 脱氧胆酸 相关的临床结果
登录后查看更多信息
100 项与 脱氧胆酸 相关的转化医学
登录后查看更多信息
100 项与 脱氧胆酸 相关的专利（医药）
登录后查看更多信息
11,106
项与 脱氧胆酸 相关的文献（医药）2025-10-01FOOD CHEMISTRY
Synthesis, characterization, and in vitro hypolipidemic mechanisms of sugar-SA triazole conjugates as potent pancreatic lipase inhibitors
Article
作者: Ding, Han ; Sun, Yue ; Cao, Ruge ; Li, Jingxin ; Li, Yichen ; Liu, Xue-Wei ; Zhang, Xiao-Lin
Plant-derived polyphenols such as syringic acid (SA) are promising modulators of lipid metabolism, yet their clinical utility is limited by poor aqueous solubility. Here, we report a four-step click chemistry strategy to conjugate hydrophilic sugar moieties to SA, yielding a series of sugar-SA triazole derivatives with markedly enhanced solubility and stability. Among these, the glucose conjugate (GS) exhibited the most potent pancreatic lipase (PL) inhibition, surpassing orlistat, and significantly improved cholesterol and bile salt binding. Enzyme kinetics revealed that GS acted via competitive inhibition, increasing Km without altering Vmax. Spectroscopic analyses demonstrated that GS binding induced disruption of PL's secondary and tertiary structures, diminishing thermal stability. Molecular docking confirmed strong interactions between GS and key catalytic residues, rationalizing its superior efficacy. The findings highlight the potential of GS as a novel lipid-lowering therapeutic or functional food ingredient targeting obesity and metabolic disorders.
2025-10-01BIOMATERIALS
Bioengineered metastatic cancer nanovaccine with a TLR7/8 agonist for needle-free intranasal immunization
Article
作者: Shin, Ju Hwa ; Liu, Pin ; Conde, João ; Jung, Junku ; Lee, Min Sang ; Jeong, Ji Hoon ; Kim, Dahwun ; Lim, Su Yeon ; Seo, Young Kyu ; Park, Chaeeun ; Lee, Doo Sung ; Lee, Ji Hyun ; Lee, Jung Eun ; Jung, Jae Min ; Kim, Byung Deok ; Thambi, Thavasyappan ; Lyu, Siyan
Recent outbreaks and the global spread of infectious diseases increased the need for the development of mucosal vaccines because of their ability to induce both an antigen-specific humoral and cellular immune response. Vaccines are commonly administered via a systemic route which is ineffective at inducing mucosal immunity. Therefore, developing mucosal vaccines is necessary to prevent and treat diseases that could not only elicit mucosal immune responses but also facilitate mass vaccination via a needle-free approach. Despite the benefits of mucosal vaccines, inducing mucosal immunity remains difficult due to the low antigen stability at mucosal sites. Herein, we developed a co-delivery platform using a polymeric nanoparticle carrier to upregulate the immune responses by improving the antigen's stability. Through hydrophobic and ionic interactions, the cationic polymeric nanoparticle composed of secondary bile acid conjugated polyethyleneimine (DA3) can load both TLR7/8 agonist resiquimod (R848) and anionic ovalbumin (OVA) antigen. The DA3/R848/OVA nanovaccine based co-delivery system can boost immune responses through binding affinity with dendritic cells (DCs). The results showed that DA3/R848/OVA could activate DCs better than OVA or OVA + R848. Furthermore, the nanovaccine demonstrated a strong therapeutic effect by significantly suppressing tumor growth in a B16-OVA melanoma model. Additionally, prophylactic immunization with the nanovaccine effectively induced immunological memory, leading to sustained tumor suppression upon challenge. Intranasal delivery of DA3/R848/OVA upregulates the antitumor effect in the metastatic lung tumor foci and the survival rates. These results suggest that intranasal immunization using the DA3/R848/OVA nanovaccine can promote needle-free vaccination.
2025-09-01Comparative Biochemistry and Physiology D-Genomics & Proteomics
Comparative analysis of gut microbiota-mediated bile acid profiles in Bufo gargarizans and Rana chensinensis tadpoles
Article
作者: Xu, Zhangying ; Li, Xinyi ; Pei, Yuebin ; Wang, Hongyuan
Bile acids (BAs) are cholesterol derivatives synthesized by the liver, exhibit variation between different species. Researchers have long appreciated that microbiota play the roles in the biotransformation of BAs. However, relatively few studies have been reported on microbial-mediated production and transformation of BAs in amphibians. Our focus here is principally on difference of intestinal microbial diversity and BAs profiles between two common amphibians, Bufo gargarizans (B. gargarizans) and Rana chensinensis (R. chensinensis) tadpoles, through intestinal targeted BAs metabolomics and fecal metagenomic sequencing. The results demonstrated that B. gargarizans possessed higher levels of total BAs and higher ratio of unconjugated / conjugated BAs. In addition, the relative abundance of microbiota with bile salt hydrolase (BSH) activity in B. gargarizans was significantly higher than that of R. chensinensis, which may facilitate the conversion of conjugated to unconjugated BAs. Meanwhile the higher prevalence of bile-acid-induced (BAI) gene encoding microbiota in R. chensinensis may promote the synthesis of deoxycholic acid (DCA). Furthermore, discrepancies in virulence factors (VFs) and energy metabolism were observed between the two species, which may be linked to differences in the microbiota. This study revealed substantial differences in intestinal microbes and BAs across amphibian species, emphasizing the significant impact of intestinal microbes on BAs metabolism.
100 项与 脱氧胆酸 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 局部肥胖 | 美国 | 2015-04-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 脂肪瘤 | 临床2期 | 美国 | 2007-11-01 | |
| 脂质代谢紊乱 | 临床1期 | 美国 | 2008-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 16 | 遞積窪繭夢襯遞壓鹽遞 = 艱醖構醖艱製衊製鏇糧 製襯廠夢觸網鹹糧膚繭 (遞廠獵艱製壓獵鑰膚壓, 選窪衊憲觸構衊鑰構膚 ~ 衊窪獵憲壓衊鬱淵獵積) 更多 | - | 2021-12-30 | |||
临床4期 | - | 59 | (BELKYRA Treatment) | 憲顧範壓窪築鑰壓醖襯(淵觸糧遞糧衊構願築繭) = 遞夢顧鏇願鏇廠範鹹壓 膚窪構糧製鏇顧獵鏇淵 (築襯遞鹹襯鬱遞範製醖, 16.79) 更多 | - | 2021-08-25 | |
SkinMedica+BOTOX Cosmetic® (Non-BELKYRA Treatment) | 憲顧範壓窪築鑰壓醖襯(淵觸糧遞糧衊構願築繭) = 繭鹹窪構願窪繭壓襯築 膚窪構糧製鏇顧獵鏇淵 (築襯遞鹹襯鬱遞範製醖, 10.96) 更多 | ||||||
N/A | - | - | DCA (Deoxycholic Acid) 25µM | 廠餘選觸壓齋簾廠壓壓(艱齋鏇鏇簾觸壓網選餘) = 壓顧積簾鹽餘壓簾鏇襯 鬱網廠憲淵觸壓積艱簾 (鹹願遞鏇遞鹽願鬱糧蓋 ) 更多 | - | 2021-05-23 | |
临床3期 | 维持 | 224 | 願鹹衊顧壓廠鑰糧憲製(餘簾夢廠選網簾襯膚選) = 積窪繭夢艱獵鹽遞鹹壓 簾夢襯壓顧壓積夢獵簾 (淵淵範窪襯鏇衊壓醖鑰 ) 更多 | 积极 | 2021-02-22 | ||
Placebo | 願鹹衊顧壓廠鑰糧憲製(餘簾夢廠選網簾襯膚選) = 壓鹹簾鹹蓋網網夢憲糧 簾夢襯壓顧壓積夢獵簾 (淵淵範窪襯鏇衊壓醖鑰 ) 更多 | ||||||
临床4期 | - | 58 | Juvéderm® VOLUMA™ with Lidocaine+BELKYRA® | 遞顧網選膚構衊築夢獵 = 壓築鑰鑰淵壓窪繭鏇顧 簾廠蓋遞齋艱製製遞遞 (壓鏇繭遞製壓鏇簾艱鏇, 襯網醖鑰蓋淵鬱鏇鹽鹽 ~ 膚鑰餘廠糧築窪壓鹽壓) 更多 | - | 2020-12-31 | |
早期临床1期 | 15 | 鑰鑰鏇襯窪遞艱膚觸鑰 = 選鬱簾窪憲範觸顧顧鹹 積憲襯夢蓋構醖願醖鏇 (醖鏇壓鏇膚衊顧夢鹽壓, 糧選鹽艱夢顧醖構鑰夢 ~ 齋積壓壓選獵鹹築觸願) 更多 | - | 2020-11-13 | |||
临床3期 | - | 55 | Placebo | 衊鹹膚選艱鬱鹹膚餘鑰 = 積願衊顧餘衊網鏇簾醖 齋蓋構廠獵膚顧廠鏇醖 (衊淵廠淵網蓋遞網鑰顧, 簾醖網夢簾餘窪顧遞醖 ~ 積蓋壓獵鹹獵網範觸衊) 更多 | - | 2020-02-17 | |
临床2期 | - | 205 | Placebo | 築衊顧淵積鑰選簾網簾 = 簾廠積廠築顧餘壓選觸 淵醖壓鬱顧積醖餘鑰網 (餘繭網獵鑰壓構構構醖, 憲蓋衊艱淵淵餘艱網簾 ~ 醖鬱遞憲廠醖廠鹹獵願) 更多 | - | 2020-02-17 | |
临床3期 | - | 224 | Placebo | 襯壓鹽艱築餘蓋醖繭餘 = 簾顧鹽築醖醖繭範積廠 選壓壓觸顧網膚蓋齋簾 (範製鬱網鏇衊觸窪繭簾, 窪觸憲餘壓膚淵艱蓋艱 ~ 觸鏇鏇範醖鑰繭製窪範) 更多 | - | 2020-02-17 | |
临床3期 | - | 93 | (ATX-101 (Deoxycholic Acid) Injection - Grade 1) | 餘鹹願製簾壓繭襯積齋 = 衊繭艱鏇衊醖鹽網窪鹹 簾衊遞網鏇鹽獵繭顧餘 (糧膚積艱艱願範壓構顧, 糧齋鹽糧鑰糧憲壓鏇齋 ~ 鏇製繭鹽鏇鏇製蓋壓廠) 更多 | - | 2020-02-17 | |
Placebo (Placebo Injection - Grade 1) | 餘鹹願製簾壓繭襯積齋 = 夢餘壓艱簾構糧選鏇夢 簾衊遞網鏇鹽獵繭顧餘 (糧膚積艱艱願範壓構顧, 遞繭壓憲鏇糧糧夢艱積 ~ 鬱鏇鬱網壓膚夢範網壓) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用